Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (478)	4/2/1999 7:55:00 PM
From: BRAVEHEART	Read Replies (1) of 1494

Hi John, Thanks for the update on the financing. I was truly concerned that there wouldn't be an announcement. Those invested or contemplating investing need to see this vote of confidence by the larger shareholders in Black & White. I couldn't agree more with your Market Cap interpretation. This company has three of the four keys to a good biotech investment. Excellent focused management. Middle & Late stage clinical product advancement. A conservative number of shares outstanding. The missing fourth element is sufficient Cash. This was a major causative factor in the stocks delisting and it's consequent out of favor status. I anticipate three stages to remedy this matter as the year unfolds. The first stage of course will be the bridge loan. This will go a long way to allay investors concerns of NTI being capable of continuing operations. It also is a significant indicator IMO of the next stage of financing operations. The deal with Big Pharma. Clearly rumors abound of a collaboration with Big Pharma currently in the works. Few can argue the market appeal of Memantine. The ideal method of partnering a product is in the later stages of development. NTI has two P-II trials while MERZ has three P-III trials ongoing. Hence a significant collaboration will go a long way to address any remaining P-III cash needs for NTI. IMO once this deal closes the risks which have caused this stock to fall so far out of favor will be removed from over head. The final stage will be the application for relisting with NASDAQ. Once this occurs I believe NTI will finally see it's true Market Capitalization. What is that value. Well the stock traded between two and three dollars without the collaboration until the delisting. I cannot see how or why it wouldn't attain that value again in the least. If in early 2000 the P-II Aids Dementia trial receives early approval and the Painful Diabetic Neuropathy trial moves into P-III it should only trade up from there. John the question no longer is "why" such a low market capitalization. The question is "when" will the above events unfold. The bridge loan should close in the next four to six weeks is my guess. The deal with Big Pharma should close by mid summer. I would think NTI could apply for re-listing soon there after. I think you will have your answer on the market-capitalization issue answered in full by the year 2000... : ) BEST WISHES Jeffrey

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next